Phage Therapy—Challenges, Opportunities and Future Prospects
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The increasing drug resistance of bacteria to commonly used antibiotics creates the need to search for and develop alternative forms of treatment. Phage therapy fits this trend perfectly. Phages that selectively infect and kill bacteria are often the only life-saving therapeutic option. Full legalization of this treatment method could help solve the problem of multidrug-resistant infectious diseases on a global scale. The aim of this review is to present the prospects for the development of phage therapy, the ethical and legal aspects of this form of treatment given the current situation of such therapy, and the benefits of using phage products in persons for whom available therapeutic options have been exhausted or do not exist at all. In addition, the challenges faced by this form of therapy in the fight against bacterial infections are also described. More clinical studies are needed to expand knowledge about phages, their dosage, and a standardized delivery system. These activities are necessary to ensure that phage-based therapy does not take the form of an experiment but is a standard medical treatment. Bacterial viruses will probably not become a miracle cure—a panacea for infections—but they have a chance to find an important place in medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 1×
“Antimicrobial resistance (AMR) accounts for approximately 700,000 deaths per year [1,2].”
BackgroundAntibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Schooley, R. T., Biswas, B., Gill, J. J., Hernandez-Morales, A., Lancaster, J., Lessor, L., Barr, J. J., Reed, S. L., Rohwer, F., Benler, S., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00954-17 · Cited by 1,254
Phage Therapy in the Postantibiotic Era
Gordillo Altamirano, F. L., & Barr, J. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00066-18 · Cited by 1,180
Phage therapy: From biological mechanisms to future directions
Strathdee, S. A., Hatfull, G. F., Mutalik, V. K., & Schooley, R. T. (2023) · Cell · doi:10.1016/j.cell.2022.11.017 · Cited by 817 · cited 7×
“The killing of the bacteria is accompanied by a decrease in phage titers until they are completely eliminated from the patient’s body with urine [11,22,23].”
BackgroundInfluentialInteractions between Bacteriophage, Bacteria, and the Mammalian Immune System
Van Belleghem, J. D., Dąbrowska, K., Vaneechoutte, M., Barr, J. J., & Bollyky, P. L. (2018) · Viruses · doi:10.3390/v11010010 · Cited by 408 · cited 1×
“…internal phages, organic compounds and detergents for reduction of endotoxins in phage lysates, phage concentration and replacement of the growth medium (here by the use of CFF), and also specialized production equipment (such as a bioreactor) or a chromatography purification system [74,80,82,83].”
MethodDedrick, R. M., Smith, B. E., Cristinziano, M., Freeman, K. G., Jacobs-Sera, D., Belessis, Y., Whitney Brown, A., Cohen, K. A., Davidson, R. M., van Duin, D., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac453 · Cited by 344
Standardized bacteriophage purification for personalized phage therapy
Luong, T., Salabarria, A.-C., Edwards, R. A., & Roach, D. R. (2020) · Nature Protocols · doi:10.1038/s41596-020-0346-0 · Cited by 274
Bacteriophages and the Immune System
Popescu, M., Van Belleghem, J. D., Khosravi, A., & Bollyky, P. L. (2021) · Annual Review of Virology · doi:10.1146/annurev-virology-091919-074551 · Cited by 178 · cited 1×
“The circulating phages are active, which determines their participation in the defense of host cells against bacterial invasion [141–144].”
Background
Cited by
Bacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
Mafe, A. N., & Büsselberg, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070820 · Cited by 18
Teymouri, S., Yousefi, M. H., Heidari, S., Farokhi, S., Afkhami, H., & Kashfi, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-024-10163-x · Cited by 11
Metadata
- Authors
- Zalewska-Piątek, B.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2023-11-22
- Volume
- 16
- Issue
- 12
- Pages
- 1638
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W4388906307
- Cited by
- 173
- References
- 10
- FWCI
- 27.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.